Macroprolactin: From laboratory to clinical practice.
Por:
Biagetti B, Ferrer Costa R, Alfayate Guerra R, Álvarez García E, Berlanga Escalera E, Casals G, Esteban Salán M, Granada Ibern ML, Gorrín Ramos J, López Lazareno N, Oriola J, Sánchez Martínez PM, Torregrosa Quesada ME, Urgell Rull E and García Lacalle C
Publicada:
1 ene 2022
Ahead of Print:
23 abr 2021
Resumen:
Prolactin measurement is very common in standard clinical practice. It is indicated not only in the study of pituitary adenomas, but also when there are problems with fertility, decreased libido, or menstrual disorders, among other problems. Inadequate interpretation of prolactin levels without contextualizing the laboratory results with the clinical, pharmacological, and gynecological/urological history of patients leads to erroneous diagnoses and, thus, to poorly based studies and treatments. Macroprolactinemia, defined as hyperprolactinemia due to excess macroprolactin (an isoform of a greater molecular weight than prolactin but with less biological activity), is one of the main causes of such erroneous diagnoses, resulting in poor patient management when not recognized. There is no unanimous agreement as to when macroprolactin screening is required in patients with hyperprolactinemia. At some institutions, macroprolactin testing by polyethylene glycol (PEG) precipitation is routinely performed in all patients with hyperprolactinemia, while others use a clinically based approach. There is also no consensus on how to express the results of prolactin/macroprolactin levels after PEG, which in some cases may lead to an erroneous interpretation of the results. The objectives of this study were: 1. To establish the strategy for macroprolactin screening by serum precipitation with PEG in patients with hyperprolactinemia: universal screening versus a strategy guided by the alert generated by the clinician based on the absence or presence of clinical symptoms or by the laboratory when hyperprolactinemia is detected. 2. To create a consensus document that standardizes the reporting of prolactin results after precipitation with PEG to minimize errors in the interpretation of the results, in line with international standards.
Filiaciones:
Biagetti B:
Servicio de Endocrinología y Nutrición, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
Ferrer Costa R:
Servei de Bioquímica, Laboratoris Clínics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España
Alfayate Guerra R:
Laboratorio de Análisis Clínicos, Hospital General Universitario de Alicante, Alicante, España
Álvarez García E:
Servicio de Análisis Clínicos, Hospital do Meixoeiro, CHU de Vigo, Vigo, Pontevedra, España
Berlanga Escalera E:
Laboratori Parc Taulí, Hospital Universitari de Sabadell, Sabadell, Barcelona, España
Casals G:
Servicio de Bioquímica i Genética Molecular, Hospital Clínic Universitari, IDIBAPS, Barcelona, España
Esteban Salán M:
Laboratorio de Bioquímica, Hospital Universitario Cruces, Barakaldo, Vizcaya, España
:
Servicio de Bioquímica Clínica, Hospital Universitari Germans Trias i Pujol, Universidad Autónoma de Barcelona, Badalona, Barcelona, España
Gorrín Ramos J:
Servicio de Boquímica, Laboratorio de Hormonas y Biomarcadores, Hospital General Universitario Gregorio Marañón, Madrid, España
López Lazareno N:
Servicio de Boquímica, Laboratorio de Hormonas y Biomarcadores, Hospital General Universitario Gregorio Marañón, Madrid, España
Oriola J:
Servicio de Bioquímica i Genética Molecular, Hospital Clínic Universitari, IDIBAPS, Barcelona, España
Sánchez Martínez PM:
Unidad de Gestión Clínica de Bioquímica Clínica, Hospital Universitario Virgen Macarena, Sevilla, España
Torregrosa Quesada ME:
Servicio de Análisis Clínicos, Laboratorio de Hormonas, Hospital General Universitario de Alicante, Alicante, España
Urgell Rull E:
Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Barcelona, España
García Lacalle C:
Servicio de Análisis Clínicos, Hospital Universitario Severo Ochoa, Leganés, Madrid, España
|